Study NumberStudy VersionYear StartedStudy TitleStudy DescriptionStudy StatusPublication NumberStudy LeadersTeams
113 2017Haemoglobin screening and deferral policies Active Di Angelantonio, van den HurkDS
112 2017Older donors study Active GoldmanDS
111 2017Pediatric Transfusion Medicine Education Active Haspel, FungCTS
110 2017Titer Products for SafetY: TIPSYMinor incompatible platelet transfusions are common practice, yet plasma has historically been provided in a strictly ABO compatible manner. However, transfusions of group A plasma and group O whole blood to recipients of unknown blood group in emergencies are becoming common and are situations where minor incompatible plasma might be transfused. Blood products with high titer anti-A and/or anti-B have a greater risk of causing hemolysis in a recipient with the corresponding A and/or B antigen. Currently, there are no universally accepted standards for the method of performing the titer testing or for the definition of a “high” titer antibody. Between blood banks, various titer methods are used and different thresholds are used to designate “high” titer units. The goal of this study is to capture the titer testing methods for plasma, single donor platelet (SDP), and whole blood units and to elucidate the prevalence of “high” titer units using the local definitions. Research Questions 1. What are the various titer testing methods used for plasma, SDP and whole blood units? 2. What is the prevalence of high titer units by donor blood group (i.e. what is the high titer failure rate by donor blood group)? 3. Is there seasonal, or month to month variation in the frequency of detecting high titer units?Active Dunbar, Harm, YazerCTS
109 2017Effect of Having a Surgical RBC Schedule on the General Availability of rbcs pre-Incision: EHSS GAI Active Yazer, CohnCTS
108 2017Critical values List for Blood Bankers Active ShazCTS
107 2017Better Understanding of Mfi cut-offs for Platelet Transfusions in Refractory Patients: BUMPER Active CohnCTS
106 2017Oneg Product Transfusion, Inventory Management and Utilization during Shortage: OPTIMUSThe goal of this study is to determine how utilization of ONEG RBC units can be reduced using various switching rules. This will be a pragmatic, retrospective descriptive study using actual transfusion data from your site. The intention of this study is to determine how many ONEG RBC units could be saved, for example, by lowering the automatic switching age to facilitate decision making during times of shortage in a graded manner, e.g., if the ONEG inventory needs to be increased by 10% during a shortage, perhaps the switching age needs to be lowered by 5 years, if a 20% increase is required perhaps a 10 year reduction is temporarily needed until the inventory returns to its usual level.Active Dunbar, YazerCTS
105 2017Surveys in Transfusion Active StanworthCTS
104 2017Platelet additive storage lesion mitigation induced by pathogen reduction Active van der MeerCC
103 2017Autologous Platelet Rich Plasma (aPRP) SurveyAutologous platelet rich plasma (aPRP) is widely used by orthopedic surgeons for chronic ‘wear and tear’ injuries, and by general surgeons for hastening wound and incision closures. Autologous PRP is often manufactured at the bedside in outpatient clinics, and in the operating theater. In the United States the FDA has approved the devices used to isolate aPRP, but has left the application of aPRP to the non-regulated area of ‘scope of medical practice.’ As a result the quality of the aPRP and its applications are not regulated. Studies have found that many of the aPRP isolation kits give highly irregular yields, with little enrichment of the platelet-rich-plasma fraction. Quality control efforts by orthopedic surgeons and other users are not known. The current range of aPRP usage is not easily assessed. We have developed a survey to discover whether aPRP is used in BEST member hospitals, and whether the Blood Bank is involved in quality control measures.Active CohnCC
102 2017Multicenter study on essentials for novel cellular therapy products manufacturing practicesAt the frontier of Transfusion Medicine and Transplantation the field of Cellular Therapy is emerging. Most Novel cellular therapy products are produced under IND. The manufacturing protocols may vary depending on the type of cellular product (e.g. mesenchymal stromal cell, pancreatic islet, natural killer cells, or T regulatory lymphocytes…). Interestingly, the manufacturing practices may also vary with the institution under which the investigative protocol is filed. The purpose of this study is to uncover the variations in manufacturing practices for similar cellular therapy products across different Cellular Processing Laboratories in institutions worldwide. The results of this survey may allow the identification of the essentials of manufacturing practices to be recommended for specific cellular therapy products at different stages of manufacturing (i.e. collection, ex vivo manipulation or expansion, distribution, or preparation for infusion). Active FontaineCT
101 2016Effect of Blood Donation on Elevated Blood Pressure Active GreinacherDS
100 2016Longitudinal OBservational revieW of Ethnic Donors Giving Erythrocytes: LOB Wedge Completed106, 109YazerDS
99 2016WARM 2: RBC Selection Practices Active Ziman, DelaneyCTS
98 2016Inventory of Committee Evaluated Hospital Quality Indicators - ICE HoQuI Completed107YazerCTS
97 2016Informed Consent in Blood Transfusion Active Fung, Haspel, ZellerCTS
96 2016Empiric use of 4 factor PCCs with life-threatening bleeds Active GorlinCTS
95 2016Determining Workload Capacity of CT Processing LaboratoryAssessing the day-to-day capacity for the SCL is challenging yet necessary to ensure patient safety, staff well-being/retainment and ultimately, sustained productivity. Moreover, SCLs are often requested to justify resource utilization and budgeting requests in the context of other comparable HSC laboratories. However, standards on how to determine daily/weekly operational capacity and benchmark data for the industry are not readily available. Some unique aspects of SCL operations which make comparing one laboratory to another are wide variation in hands-on-time required for various procedures (e.g. numbers of allogeneic cord blood/bone marrow/apheresis products requiring red cell reduction vs. unmanipulated or autologous products) and the availability of automation. In addition, the scope of practice (e.g. whether SCL staff are present at collection site and/or perform bedside thawing) also varies. In addition, SCLs differ from other clinical labs in varying availability of software to manage testing, reporting, and integration of patient data. To address these gaps we undertook time studies of ~20 common procedures/tasks in three distinct but large academic transplant programs using manual processing. Staff were instructed to time actual hands-on time spent performing tasks, including necessary paperwork/data entry (Table 1). Tasks such as infusion of cryopreserved products and preparation of HPC for shipping required significant time investment commensurate with HPC processing. Also DLI product manipulations take significant time. Since, many SCL laboratories are not involved in product infusions or do not serve as NMDP sites, inclusion of these activities would significantly alter transplant volume capacity per FTE. Active YoungCT
94 2016Trends for Collections Completed97 DS
93 2015 Evidence-Based Guidance for Donor Reaction Management Active VassalloDS
92 2015ABOut HLA Completed98DunbarDS
91 2015Resuspension of Cryopreserved Platelets in PAS Active Dumont, JohnsonCC
90 2015Interlaboratory Measurements of Cryopreserved Platelets Active Noorman, JohnsonCC
89 2015Will Issue:Crossmatch ratio Keep Erythrocytes Tight -WICKET Completed101Yazer, ZimanCTS
88 2015How many AB unitS Were Infused - HABS WIN Active YazerCTS
87 2015Safety of Thawed A in Trauma - STATTo better understand the current use of plasma in trauma resuscitation, a survey was developed, validated, and distributed via e-mail to 121 American trauma centers.Completed89, 113Yazer, DunbarCTS
86 2015GRoup O Utilization Patterns - GROUP Completedpublication acceptedYazerCTS
85 2015Blood Collection and Processing Methods for Serum Eye Drops Completed108Irving, MarksCC
84 2014Ultra-Massive Transfusion Completed92Dzik, YazerCTS
83 2014Hemolysis Measurement Standardization Active105AckerCC
82 2014Survey for Component Transformation Active-Manuscript in Preparation CardiganCC
81 2014Dendritic Cells and FunctionDendritic cells can be manufactured using different methods and starting cellular material. Two methods of DC isolation and culture will be evaluated, immunomagnetic separation and elutriation for monocyte enrichment. Active GarritsenCT
80 2014MSCs: Inter-laboratory variabilityBecause of their reparative, immunomodulatory and angiogenic potential, autologous and allogeneic human mesenchymal stem cells (hMSCs) are produced in cultures for a wide variety of clinical applications. However, there is a lack of standardized methodologies to culture human MSCs and it is unknown as to what the impact of different laboratories strategies have on the function of cultured derived hMSCs. To assess inter-laboratory variability associated with culturing hMSC, 3-4 different laboratories will receive three different bone marrows from the same source and culture the hMSC using their own laboratory methodologies. At passages 1, 2, and 3, viable cell counts will be performed and the fold-increases and doubling times will be determined. At the end of passage number #3, immunophenotyping will also be performed and harvested cells will be sent for microarray analysis. The purpose of this study is to assess the inter-laboratory variability associated with producing hMSCs by different laboratories using the same starting source of hMSC and each laboratory using its own culture conditions. The following characteristics will be evaluated a cell count and minimally immunophenotype for the following markers: CD105, CD73, CD90, CD34, CD45, CD14. In addition, cells will be analyzed for gene expression at NIH.Manuscript in Preparation Reems, StroncekCT
79 2014Transfusion Reaction Guidelines Active Delaney, ZimanCTS
78 2014DARA-DTT Study Active95, 100KaufmanCTS
77 2014An International Study of Donor Demographic TrendsThis study will compare and interpret donor and general population age trends in 3 years (2001, 2006 & 2011) amongst blood collectors in various jurisdictions to hypothesize about differing social values and donor motivations as well as identify successful past and future blood center donor selection, recruitment & retention practices.Active GoldmanDS
76 2014A Case-Control Study of Donor Factors Associated with Unacceptably Low pH in Stored Apheresis PlateletsUsing participant QC data, this study will attempt to identify medical & demographic donor characteristics potentially associated with an increased risk of poor platelet storage, as reflected by unexplained low pH at unit issue or outdate.Completed104GermainDS
75 2013D sensitization after platelet transfusion: ADAPT Completed88CidTS
74 2013Irradiation of Red Cells Active-Manuscript in Preparation de Korte, Cardigan, DevineCC
73 2013Influencing Plasma uSage With Information that is Computerized and Helpful: IPSWICH Closed Yazer, BrooksCTS
72 2013Warm Autoimmune Hemolytic Anemia: Testing and Transfusion Practices Completed99ZimanCTS
71 2013Survey to identify release criteria being utilized with cellular therapy products-revisted Active SzczepiorkowskiCT
70 2012Comparison of MSC Manufactured at Different CentersMesenchymal Stem Cells are widely used in clinical trials. They are manufactured in different centers with variable conditions including donor, source of starting material, culture conditions etc. Their use and release criteria are also variable. The focus of this study is to answer the following questions: 1. Describe differences in BMSC manufacturing among centers 2. Identify differences, if any, due to manufacturing on product quality 3. Identify the most important sources of variability Each participating site provides several samples for analysis. The evaluation will include descriptive characteristics (e.g. starting material, methods, surface marker expression etc); as well as gene expression analysis. Additional studies will include murine transplantation studies with assessment of in vivo bone and cartilage formation and support of hematopoiesisCompleted111StroncekCT
69 2012Low Level Platelet & Red Cell Counting Send-around Active van der Meer, BlairCS
68 2012Preventing HDFN with Transfusion Matching of Females of Childbearing Potential - AMIGO Completed102DelaneyCTS
67 2012Development of a standardized case report form for bleeding assessment in clinical trials Active  CTS
66 2012Viability Testing in Cryopreserved Thawed CT Products Active TakanashiCT
65 2012Viability and Functional Evaluation of Cryopreservation Methods for T cell PopulationsPeripheral blood mononuclear cells (PBMNC) collected from leukaphereses of allogeneic hematopoietic stem cell (HSC) donors are often given to the transplantation recipients as prophylactic or therapeutic immunomodulatory therapy. This product has been generically named donor-derived leukocyte infusion (DLI). For decades, the reference cryoprotectant for these products was 10% DMSO. However, several studies on HSC engraftment have indicated that combinations of 4-5% DMSO and hydroxyethylstarch provide similar (or even better) post-thaw viability/function. Whether the functional response of different T-cell populations is similar or not is unknown. Hypothesis: 1. Cryopreservation may induce significant T-cell viability and functional defects which may differ for different T cell populations. 2. Different T cell populations may differ in their optimal cryopreservation medium requirements. In the participating sites the apheresis product will be collected and cryopreserved in different cryopreservation solutions (DMSO 5%; 10%; CryoStor 5% and CryoStor 10%). Fresh and cryopreserved cells will be shipped to the central laboratory (Univ of Cincinnati). The analysis will include testing for immunophenotype, viability, proliferation and cytokine release.Completed110CancelasCT
64 2012Collection and Storage Solutions for CT Products Active HaspelCT
63 2011TOFU: Trial of feedback on blood use Active Kaufman, Yazer, StanworthTS
62 2011Counting platelets in thrombocytopenic samples Completed85LozanoCS
61 2011Anemia prior to surgery Closed WatersCTS
60 2010Intracellular vs extracellular cryopreservation agent Active MathewCT
59 2010Critical appraisal of tools used to capture bleeding in clinical trials Active StanworthCTS
58 2010Activation markers in platelets Completed83DevineCC
57 2010Standardisation of red cell biochemical assays Completed80HessCC
56 2010Clinical description of transfusion reactions Withdrawn  TS
55 2009What do physicians know about transfusing Completed84, 86, 91, 93HaspelTS
54 2009Age of Blood Studies: Methodological Pitfalls Completed65van de WateringCS
53 2009Survey of Repetitive Stress Injury and Contact Dermatitis Withdrawn  CS
52 2009TM Assistant: a programe for differential diagnosis of acute transfusion reactions Closed HeddleCTS
51 2008Platelet quality after different pre processing hold conditions Completed73de WildtCC
50 2008Haemolysis from national quality control data Completed58HessCC
49 2008Nucleotide profiles in red cells relative to R&S Active DumontCC
48 2008Bacterial contamination of CT products Withdrawn  CT
47 2008Transportation of CT products Completed64McKenna, PamphilonCT
47B2010Optimal Transport Conditions for Non-Mobilized Apheresis Collections Active McKennaCT
46 2007Modelling effect of shortening red cell life on inventory Completed83BeckmanTS
45B2007Guidelines for reporting platelet trials in transfusion medicine: Phase 2 – Delphi technique Completed79HeddleCS, TS
45A2007Guidelines for reporting platelet trials in transfusion medicine: Phase 1 – Young investigators Completed61HeddleCS, TS
44 2007Questionnaire on ABO incompatible platelets Completed59LozanoCS
43 2007Haemoglobin measurement of blood units matched to patients Completed62HervigCS
42 2006Qualitative Evaluation for Safer Transfusion (QUEST) Completed78HeddleTS
41 2006Whole blood overnight storage Completed66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76 CC
40 2006Reduction in variation of performance of antibody titrations Completed55AuBuchonCC
39 2006Survey of transfusion utilization methods Active-Manuscript in Preparation Tinmouth, StanworthTS
38 2006Statistical process control for blood sample collection Completed54BeckmanTS
37 2006Comparison of single- and double-label approaches to red cell recovery studies and evaluation criteria Completed53Dumont, AuBuchonCS
36 2005Functional assays for evaluation of dendritic cells Closed4Eichler, SzczepiorkowskiCT
35 2004Platelet quality control standardization send-around Completed77van der Meer, CardiganCC
34 2004Bacterial contamination detection questionnaire Completed52Prowse 
33 2004Comparison of radiolabeling and flow cytometry for determining platelet kinetics Active-Manuscript in Preparation van der Meer, SlichterCTS
32 2006Standardisation of the CFU assay Completed82ReemsCT
31 2003Randomized controlled trial of a simple intervention to improve performance of the pretransfusion bedside identity check (PROBE Study) Completed49MurphyTS
30 2003Survey to understand cell recovery in thawed cord blood samples Completed51BrandCT
29A2003Survey to identify release criteria being utilized with cellular therapy products Closed SzczepiorkowskiCT
29B2003Transportation/shipping survey Completed60PamphilonCT
28 2003Inter-lab pilot study on the quality characteristics of dendritic cells Completed50EichlerCT
27 2003A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia Completed40HeddleCS
26 2003Comparison of in vitro analyses of red cell units across multiple labs Completed37HessCC
25 2003Comparison of Recovery and Survival of Extended Storage PRP and Buffy Coat Platelets in Health Volunteers Completed63DumontCS
24 2003Effect of two days’ shipping on platelet function and biochemical analyses Completed35Dumont, GullikssonCC
23 2003Effect of supranormal pH on radiolabeled platelet recovery and survival Completed38Dumont, GullikssonCS
22 2002Evaluation of the hemostatis efficacy and the platelet utilization rates of low versus standard dose platelet therapy (SToP) Completed26, 29, 31 CS
21 2002Effect of storage medium and protein source on ESC and HSR Completed30 CC
21A2001Effect of storage medium and protein source on ESC and HSR (pilot study)  Completed24 CC
20 2001Effects of interruption of agitation of platelet concentrates stored in PAS environment (pilot study) Completed32 CC
19A-F2001Evaluation of in vitro asay utilized to evaluate cord blood hemopoietic stem cell products Completed33, 39 CT
18 2001The COBS (collection of blood samples) study Completed25, 27 CT
17 2001Storage of platelets in additive solutions: In vitro effects of potassium and magnesium (pilot study) Completed22, 23 CC
17A2000Storage of platelets in additive solutions: In vitro effects of potassium and magnesium (pilot study) Completed21 CC
16  Evaluation of the influence of conditions encountered during the transportation of platelet components from blood centers to hospitals on platelet quality (See Study 20) Closed  CC
15 1999Cord blood filtration study Completed41 CT
14B SToP: Analysis of adjudication process Completed96 CS
14A SToP Main study Completed57 CS
13 1996CD34+ cell count Completed18 CT
12 1996Platelet counting study Completed15, 20, 36 CC
11 1996Automated white cell count in white cell reduced blood components Completed19 CC
10 1996Platelet transfusion in routine practice Closed   
9 1996In vitro assays for evaluation of the properties of stored platelets: interlaboratory study to evaluate lactate, lactate dehydrogenase and CD62 parameters Completed16  
8 1995Multicenter evaluation of the 3% PFA method for white cell counting in leukocyte-reduced red blood cells Completed11  
7 1994Use of in vitro assays: evaluation of platelet properties using the extent of shape change, and response to hypotonic stress assays Completed14  
6 1994Cellular harvests in blood components prepared with buffy-coat removal versus methods based on platelet-rich plasma Completed6, 7, 13  
5 1994Relation between swirling and other methods for PC quality control Completed4, 5  
4 1994Evaluation of platelet swirling vs pH in routine PC Completed9  
3 1993Quality control of platelet concentrates by shimmering inspection Completed2, 4  
2 1992Counting leukocytes by Nageotte chamber in leukocyte-depleted red blood cells Completed3, 10  
1 1991Flow cytometry vs Nageotte chamber white cell counting methods Completed1